National Center for Tumor Diseases - University Hospital Heidelberg
National Center for Tumor Diseases - University Hospital Heidelberg
Heidelberg, Germany1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 2 | 2026-09-11 | NCT05306041 |